The AVEN Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the AVEN gene in the human near-haploid HAP1 cell line. This product delivers a heterogeneous pool of cells carrying diverse loss-of-function alleles, providing a robust tool for studying apoptosis biology without the limitations of single-clone variability. CRISPR/Cas9-mediated gene disruption ablates AVEN protein expression, enabling researchers to interrogate its function in cell death regulatory networks. The polyclonal format is well-suited for bulk biochemical and phenotypic assays, offering a representative snapshot of knockout effects across a population.
The HAP1 host cell line is a fibroblast-like, near-haploid cell model originally derived from the KBM-7 chronic myeloid leukemia line, carrying a male karyotype. Its near-haploid genome simplifies genetic manipulation and enhances the efficiency of CRISPR/Cas9 editing, making HAP1 a preferred platform for functional genomics screens and targeted gene studies. The cells exhibit adherent growth and maintain key apoptotic signaling machinery, rendering them a physiologically relevant context for evaluating apoptosis modulators. This genetic background combines robustness with simplicity, facilitating reproducible experimental workflows in both basic and translational research.
AVEN functions as an inhibitor of intrinsic apoptosis by physically bridging Bcl-xL and Apaf-1, thereby obstructing Apaf-1-mediated activation of caspase-9 and the downstream executioner caspase-3. This interaction prevents apoptosome assembly and attenuates cytochrome c-induced cell death. AVEN expression is regulated by upstream signals including p53 and growth factor pathways, positioning it at a critical node where survival cues converge. The protein also interacts with Bcl-2 and pro-caspase-9, reinforcing its role within the Bcl-2 family signaling axis. Through these interactions, AVEN modulates caspase activation cascades and mitochondrial outer membrane permeabilization, ultimately influencing cellular decisions between survival and apoptosis.
Knockout of AVEN in the HAP1 context removes a key apoptotic brake, sensitizing cells to intrinsic death stimuli such as DNA-damaging agents or kinase inhibitors. This sensitization is particularly relevant for modeling chemoresistance in hematologic malignancies, including acute myeloid leukemia and chronic lymphocytic leukemia, where AVEN-mediated protection can blunt drug efficacy. The loss-of-function background allows dissection of AVEN??s contribution to mitochondrial cytochrome c release and subsequent caspase-9/-3 signaling, enabling precise characterization of death pathway engagement. By eliminating AVEN??s inhibitory influence, researchers can quantify changes in stimulus-response thresholds and identify synthetic lethal interactions.
This polyclonal knockout cell pool is optimized for diverse experimental applications, including apoptosis regulation studies, chemosensitivity profiling, and intrinsic pathway dissection. Typical assays include western blotting for cleaved caspase-3 and PARP to monitor apoptosis execution, flow cytometry with Annexin V/propidium iodide staining to quantify cell death, and caspase activity measurements to assess enzymatic activation. Co-immunoprecipitation experiments can confirm loss of AVEN-Bcl-xL complexes, while RT-qPCR verifies AVEN transcript disruption. Drug sensitivity assays using etoposide or staurosporine enable comparative analysis of knockout versus wild-type responses. For additional technical details or ordering information, please contact Ascent Research.
